WHOLE LIVER RADIATION DOSE ESCALATION FOR INTRAHEPATIC CANCERS

肝内癌的全肝脏辐射剂量递增

• 批准号: 6303437
• 负责人: CORNELIUS J MCGINN
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6303437
• 关键词: clinical research; clinical trials; human subject; human therapy evaluation; liver neoplasms; neoplasm /cancer radiation therapy; radiation therapy dosage; radiobiology; whole body irradiation dosage

Although radiation has proven efficacy in the treatment of cancers that started in or spread to the liver, its usefulness is limited by the low dose that can be safely tolerated. The dose limiting side effect is referred to as Radiation Induced Liver Disease (RILD). This trial will assess the feasibility of whole liver radiation dose escalation utilizing a blood thinning agent (heparin) which may prevent the development of RILD, and alteplase (a blood clot dissolving agent) to reduce the severity of RILD should it occur. This strategy has been used to successfully to treat a similar toxicity which occurs following bone marrow transplant.

尽管放射治疗开始于肝脏或扩散到肝脏的癌症已被证明有效，但其有效性受到可安全耐受的低剂量的限制。剂量限制性副作用称为放射性肝病(RILD)。这项试验将评估使用血液稀释剂(肝素)和阿尔替普酶(一种血液凝块融解剂)来降低RILD发生时的严重程度，从而提高全肝辐射剂量的可行性。这一策略已经成功地用于治疗骨髓移植后发生的类似毒性。